Drug Search Results
More Filters [+]

Dordaviprone

Alternative Names: Dordaviprone, onc-201, onc201, onc 201
Latest Update: 2024-09-03
Latest Update Note: News Article

Product Description

ONC201 is the founding member of the imipridone class of anti-cancer small molecules which selectively targets Dopamine Receptor D2 (DRD2) and ClpP. ONC201-mediated cell death occurs via induction of the integrated stress response and upregulation of apoptotic factors, such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). It is dosed orally and has been well-tolerated and shown clinical activity in Phase I and II trials for specific advanced cancers. (Sourced from: https://www.chimerix.com/our-pipeline/imipridones/onc201/)

Mechanisms of Action: D2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chimerix
Company Location: DURHAM NC 27713
Company CEO: Michael A. Sherman
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dordaviprone

Countries in Clinic: Austria, Denmark, France, Germany, Italy, Netherlands, Spain, United States

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: Glioma

Phase 2: Endometrial Cancer|Meningioma

Phase 1: Brain Cancer|Healthy Volunteers|Obesity|Oncology Unspecified|Urogenital Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BIOMEDE 2

P3

Recruiting

Glioma

2028-09-01

PNOC022

P2

Active, not recruiting

Glioma

2027-11-20

ONC201-108

P3

Recruiting

Glioma

2026-12-15

ACTION

P3

Recruiting

Glioma

2026-08-01

Recent News Events